Clinical trials: Neoplasm, Ovarian
Ovarian Cancer, Epithelial, Gastric Cancer
A Study of NX-1607 in Adults With Advanced Malignancies
This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.
- Conditions
- Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT05107674
- Testing
- NX-1607, Paclitaxel
- Where
- 17 sites in United States, United Kingdom
- Volunteers
- 345 people
- Sponsor
- Nurix Therapeutics, Inc.
Polycystic Ovarian Syndrome (PCOS), Reproductive Health
Management of Polycystic Ovarian Syndrome-associated Reproductive Dysfunction Through Kefir Supplementation
Polycystic ovary syndrome (PCOS) affect around 6-12% of women of age 18-25 years. Kefir contains bioactive compounds such as lactic acid bacteria, yeast, peptides, polysaccharides and organic acids and acts as a good probiotic…
- Trial name
- NCT07711782
- Testing
- (C0) Control group, (G1) Experimental group
- Where
- Pakistan
- Volunteers
- 50 people
- Sponsor
- University of Lahore
Ovarian Cancer, Peritoneal Cancer
Abraxane/Bevacizumab
The protocol will study the effect of the combination of two drugs-Abraxane and Bevacizumab-on a subject's ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
- Trial name
- NCT01821859
- Testing
- Abraxane, Bevacizumab
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- OHSU Knight Cancer Institute
Breast Cancer
TRIal evalUating the Menstrual and Ovarian Function of Young Breast Cancer Patients Treated With a cycloPHosphamide-free Regimen
Recently, there has been a rising trend of delaying childbearing and hence more women are diagnosed with breast cancer before completing their families.
- Trial name
- TRIUMPH (NCT02053597)
- Testing
- Doxorubicin, paclitaxel
- Where
- 4 sites in Belgium
- Sponsor
- Jules Bordet Institute
Ovarian Cancer
Artificial Intelligence Model for Growth Prediction of Ovarian Cancer Organoids
The present study aims to collect early bright field image of patient-derived organoids with ovarian cancer. By leveraging artificial intelligence, this study will seek to construct and refine algorithms that able to predict…
- Trial name
- NCT06317610
- Testing
- growth prediction of ovarian cancer organoids in the frame of bright field image by leveraging AI
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Chongqing University Cancer Hospital
Fallopian Tube Cancer, Ovarian Cancer
S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. It is not yet known whether giving paclitaxel for a shorter period of time is as effective as a standard…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
- Trial name
- NCT00003120
- Testing
- paclitaxel
- Where
- 93 sites in United States
- Volunteers
- 308 people
- Sponsor
- SWOG Cancer Research Network
Recurrent Gynecological Cancer, Metastatic Cervical Cancer
Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer
This research study is evaluating the safety and effectiveness of 2 immunotherapy drugs in combination with radiation therapy as a possible treatment for recurrent or metastatic gynecologic cancer.
- Conditions
- Recurrent Gynecological Cancer, Metastatic Cervical Cancer, Metastatic Ovarian Cancer, Metastatic Vaginal Cancer
- Trial name
- NCT03277482
- Testing
- Durvalumab, Tremelimumab, Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Dana-Farber Cancer Institute
Polycystic Ovarian Syndrome, Insulin Resistance
Effect of Whole Body Vibration on Insulin Resistance in Females With Polycystic Ovarian Syndrome
The purpose of this study is to investigate the effect of whole body vibration on insulin resistance in females with polycystic ovarian syndrome
- Trial name
- WBV (NCT05215223)
- Testing
- whole body vibration, Treadmill
- Where
- Egypt
- Volunteers
- 46 people
- Sponsor
- Cairo University
Solid Tumor
A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors
The proposed clinical study is a Phase 1/2a trial to investigate the safety, tolerability, pharmacokinetics and clinical activity of anti-HLA-G CAR-T cells IVS-3001 administered to subjects with previously treated, locally…
- Trial name
- NCT05672459
- Testing
- Single Injection of IVS-3001- Anti - HLA-G CAR-T cells, Fludarabine phosphate, Cyclophosphamide
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Relapsed or Refractory Germ Cell Tumours, Advanced Relapsed or Refractory Endometrial Cancer
A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)
This study is open to adults with advanced germ cell tumours, endometrial cancer, or ovarian cancer whose previous treatments were not successful.
- Conditions
- Advanced Relapsed or Refractory Germ Cell Tumours, Advanced Relapsed or Refractory Endometrial Cancer, Advanced Relapsed or Refractory Ovarian Cancer
- Trial name
- NCT07306559
- Testing
- BI 3820768
- Where
- 13 sites in United States, Belgium and 4 more
- Volunteers
- 187 people
- Sponsor
- Boehringer Ingelheim
Patient Reported Outcome Measures, Ovarian Neoplasms
The Possible Influence of Different Follow-up Modalities on Overall Survival in Ovarian Cancer
The study is designed as an observational cohort study, aiming to evaluate, whether a structured recording of symptoms by a mobile app contributes insight in the follow-up modalities of ovarian cancer patients.
- Trial name
- ECOvar (NCT05352217)
- Testing
- Mobile app ovarian cancer followup (ePRO)
- Where
- 4 sites in Switzerland
- Volunteers
- 7 people
- Sponsor
- Stiftung Swiss Tumor Institute
Polycystic Ovary Syndrome (PCOS), Insulin Resistance Syndrome
Evaluation of MG53 (TRIM72) Levels in Women With Polycystic Ovary Syndrome: An Observational Study
Purpose of the Study: This study is being conducted to examine a protein called MG53 (also known as TRIM72) in women with polycystic ovary syndrome (PCOS).
- Trial name
- PCOSMG53 (NCT07094776)
- Testing
- No intervention (observational study)
- Where
- Turkey (Türkiye)
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Havva Betül Bacak
Ovarian Cancer Stage III, Ovarian Cancer Stage IV
Tumor Microenvironment in Ovarian Cancer
A detailed understanding of molecular mechanism of cancer genesis is fundamental to develop innovative and personalized therapies.
- Trial name
- MICO (NCT06272240)
- Testing
- Ovarian Cancer Organoids
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- University of Udine
Fallopian Tube Cancer, Ovarian Cancer
Mifepristone in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
RATIONALE: Progesterone can cause the growth of ovarian epithelial cancer , primary peritoneal cancer, or fallopian tube cancer.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00459290
- Testing
- mifepristone
- Where
- 22 sites in United States
- Volunteers
- 24 people
- Sponsor
- Gynecologic Oncology Group
Ovarian Cancer, Ovarian Neoplasms
A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)
This study, ELU- FRα-1, was focused on adult subjects who have advanced, recurrent or refractory folate receptor alpha (FRα) overexpressing tumors considered to be topoisomerase 1 inhibitor-sensitive based on scientific…
- Conditions
- Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Endometrial Cancer
- Trial name
- NCT05001282
- Testing
- ELU001
- Where
- 18 sites in United States
- Volunteers
- 79 people
- Sponsor
- Elucida Oncology
Renal Cell Carcinoma, Ovarian Carcinoma
OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults
The study hypothesis is that a lower starting dose of anticancer tablet treatments can lead to better treatment tolerability in older patients, while the benefits of treatment can be the same.
- Conditions
- Renal Cell Carcinoma, Ovarian Carcinoma, Thyroid Carcinoma, Breast Carcinoma
- Trial name
- OPTI-DOSE (NCT05949424)
- Testing
- Olaparib, Lenvatinib, Sunitinib
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- University Medical Center Groningen
Polycystic Ovarian Syndrome
Follicular Synchronization in PCOS Patients Undergoing ICSI
The use of GnRH antagonist protocol nowadays is the slandered protocol of controlled ovarian stimulation in patients with poly cystic ovarian syndrome (PCOS) because it decreases the incidence of OHSS(1, 2).
- Trial name
- NCT04069117
- Testing
- letrozole 2.5mg (Femara; Novartis Pharma Services, Basel, Switzerland)
- Where
- Egypt
- Volunteers
- 200 people
- Sponsor
- Mansoura University Hospital
Cancer
Colony-Stimulating Factors in Treating Children With Recurrent or Refractory Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as thrombopoietin and G-CSF may increase the number of immune cells found in…
- Trial name
- NCT00003597
- Testing
- recombinant human thrombopoietin, carboplatin, etoposide
- Where
- 24 sites in United States, Australia
- Volunteers
- 16 people
- Sponsor
- Children's Oncology Group
Ovarian Cancer
Mesothelin as a New Tumor Marker for Ovarian Cancer
Ovarian cancer became a more and more important disease in recent years due to its first mortality rate of gynecologic malignancies. The incidence of ovarian cancer also increased in recent year in Taiwan.
- Trial name
- NCT00155740
- Where
- Taiwan
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Head and Neck Cancer, Ovarian Cancer
Deciphering Mechanisms Underlying Cancer Immunogenicity
This trial is a translational, open-label, multicentric, prospective cohort study of 1100 patients aiming to describe the PD-1 (programmed death) expression in T cells (T lymphocytes) in different solid tumors.
- Conditions
- Head and Neck Cancer, Ovarian Cancer, Cervical Cancer, Cervical Intraepithelial Neoplasia 3
- Trial name
- DECIDE (NCT03958240)
- Testing
- Blood samples, tumor biopsy specimens and ascites samples will be collected.
- Where
- 3 sites in France
- Volunteers
- 1,100 people
- Sponsor
- Institut Claudius Regaud
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.